Solriamfetol is a dopamine and norepinephrine reuptake inhibitor used to improve wakefulness. It is approved in the United States for narcolepsy and obstructive sleep apnea, with a listed dose range of 75–150 mg/day. Inhibition of DAT and NET increases extracellular dopamine and norepinephrine concentrations. Solriamfetol has linear pharmacokinetics, minimal metabolism, and renal clearance; renal impairment requires dose adjustment. Reported efficacy includes increased MWT sleep latency and improved ESS, PGI-C, and CGI-C scores. Common adverse effects include headache, decreased appetite, nausea, anxiety, and insomnia. Potential safety concerns include increased blood pressure and heart rate and QTc prolongation.